Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price objective on the stock. D. Boral Capital’s price objective would suggest a potential upside of 142.59% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Trading Down 15.1 %

Shares of Citius Pharmaceuticals stock opened at $3.71 on Tuesday. The stock has a market capitalization of $28.67 million, a price-to-earnings ratio of -0.62 and a beta of 1.30. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75. The firm’s 50-day moving average price is $4.89 and its two-hundred day moving average price is $11.49.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CTXR. Chelsea Counsel Co. raised its position in Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after buying an additional 25,000 shares during the last quarter. Miller Investment Management LP lifted its stake in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after acquiring an additional 49,640 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $29,000. Arkadios Wealth Advisors boosted its stake in shares of Citius Pharmaceuticals by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after acquiring an additional 50,000 shares during the period. Finally, Wealth Advisory Solutions LLC lifted its holdings in Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.